Page 111 - Prostate News Today

For more than two decades, University of Alabama at Birmingham researcher Susan Bellis, Ph.D., has studied how the addition of sialic acid to various proteins increases cancer resistance and oncogenicity.

Scientists at Memorial Sloan Kettering Cancer Center (MSK) have glimpsed never-before-seen details of the human androgen receptor -; the protein inside of cells that responds to male-typical hormones like testosterone.

A person's risk of developing diseases such as type 2 diabetes or breast cancer may be influenced by thousands of genetic differences.

A cancer diagnosis is scary. Some doctors say it’s time to rename low-grade prostate cancer to eliminate the ...

Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant DiseaseSEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics

Gavin Hartford takes us on his convoluted path from diagnosis to denial to cure

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers -; ATR inhibitor elimusertib and PARP inhibitor AZD5305 -; are safe and clinically beneficial in treating patients with advanced solid tumors.

Georgia counties with the highest mortality rates from four common cancers tended to be more rural, have higher poverty rates, have a higher percentage of Black residents and/or older individuals, according to researchers at the state's public medical school and Georgia Cancer Center.